Preclinical applications and studies
-
A Look At Column Reproducibility: Analysis Of Endogenous Steroid Hormones In Serum
6/30/2022
Having reproducible columns is critical for the success of batch to batch testing of stationary phases, as well as ensuring lifelong performance for the assay.
-
Increasing Chromatographic Performance Of Acidic Peptides In RPLC-MS-based Assays
6/30/2022
We demonstrate how to increase productivity in the lab and mitigate risk through increased reproducibility, recovery, and robustness of assays performed in the development and manufacturing of biopharmaceutical drug products.
-
Examining Column Reproducibility During Method Development In Clinical Labs
6/28/2022
In this study demonstrates how the HSS T3 stationary phase is a reliable stationary phase, as three batches made over a five-year span provide comparable results.
-
Engineering A PMA Study For A First-Of-Its-Kind Oncology Dx
3/8/2022
A client developed a unique solution for Colorectal cancer screening – a multi-target, noninvasive screening test that could be facilitated by patients in their homes. Gather information on how the pre-market approval (PMA) study was conducted.
-
Visual Analytics And Discovery Platform For Scientific And Clinical R&D
8/18/2021
A pharmaceutical company was looking to deploy a software solution for a small R&D group. See how an enterprise-class visualization and analytics platform enabled maximized understanding of research data.
-
Overcoming Clinical Challenges In Metabolic And Cardiovascular Disease With Metabolomics
4/10/2013
Metabolic diseases (e.g. obesity, type 2 diabetes, and hypertension) are a rapidly expanding health care concern. Although there is a high demand for novel therapies, the challenges are substantial as existing drugs typically fail due to lack of efficacy or safety, and clinical studies often extremely large and protracted.
-
Overcoming Clinical Challenges In Oncology With Metabolomics
4/10/2013
Cancer continues to be a formidable disease with an overall success rate of bringing new drugs to market of only 5-8%.
-
Streamline And Accelerate A Drug Development Plan Using The 505(b)(2) Pathway
2/19/2013
An international pharmaceutical company approached Camargo Pharmaceutical Services to help navigate the Food and Drug Administration (FDA) 505(b)(2) approval pathway for a promising drug under development designated for patients with cardiovascular disease. Product X is a prodrug that is converted in one metabolism-dependent step to produce the active metabolite of an approved drug.
-
Accelerating Preclinical Studies With Project Tracking And Optimization Software
2/13/2013
A large pharmaceutical company with globally distributed preclinical R&D operations including externalized services implemented an advanced assay/ study tracking and optimization system in conjunction with its enterprise electronic lab notebook.